vs
Amphastar Pharmaceuticals, Inc.（AMPH）とRanger Energy Services, Inc.（RNGR）の財務データ比較。上の社名をクリックして会社を切り替えられます
Amphastar Pharmaceuticals, Inc.の直近四半期売上が大きい（$183.1M vs $142.2M、Ranger Energy Services, Inc.の約1.3倍）。Amphastar Pharmaceuticals, Inc.の純利益率が高く（13.3% vs 2.3%、差は11.1%）。Ranger Energy Services, Inc.の前年同期比売上増加率が高い（-0.6% vs -1.8%）。Amphastar Pharmaceuticals, Inc.の直近四半期フリーキャッシュフローが多い（$24.6M vs $17.1M）。過去8四半期でAmphastar Pharmaceuticals, Inc.の売上複合成長率が高い（3.2% vs 1.9%）
Amphastar Pharmaceuticalsは上場されている米国の特殊製薬企業です。2004年5月に設立され、主に吸入剤および鼻腔内投与製品の開発、生産、販売を行っており、特色ある医薬品分野で事業を展開しています。
レンジャー・エナジー・サービシズ社は北米屈指の陸上油田サービスプロバイダーであり、上流の石油・ガス事業者に対して坑井完成、修井、リグ運用、生産性向上ソリューションを提供し、主に米国本土のシェール・緻密資源開発地域で事業を展開しています。
AMPH vs RNGR — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $183.1M | $142.2M |
| 純利益 | $24.4M | $3.2M |
| 粗利率 | 46.8% | — |
| 営業利益率 | 19.4% | 2.3% |
| 純利益率 | 13.3% | 2.3% |
| 売上前年比 | -1.8% | -0.6% |
| 純利益前年比 | -35.7% | -44.8% |
| EPS（希薄化後） | $0.51 | $0.14 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $183.1M | $142.2M | ||
| Q3 25 | $191.8M | $128.9M | ||
| Q2 25 | $174.4M | $140.6M | ||
| Q1 25 | $170.5M | $135.2M | ||
| Q4 24 | $186.5M | $143.1M | ||
| Q3 24 | $191.2M | $153.0M | ||
| Q2 24 | $182.4M | $138.1M | ||
| Q1 24 | $171.8M | $136.9M |
| Q4 25 | $24.4M | $3.2M | ||
| Q3 25 | $17.4M | $1.2M | ||
| Q2 25 | $31.0M | $7.3M | ||
| Q1 25 | $25.3M | $600.0K | ||
| Q4 24 | $38.0M | $5.8M | ||
| Q3 24 | $40.4M | $8.7M | ||
| Q2 24 | $37.9M | $4.7M | ||
| Q1 24 | $43.2M | $-800.0K |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
| Q4 25 | 19.4% | 2.3% | ||
| Q3 25 | 13.2% | 2.0% | ||
| Q2 25 | 24.2% | 6.1% | ||
| Q1 25 | 21.9% | 0.7% | ||
| Q4 24 | 24.2% | 6.2% | ||
| Q3 24 | 29.8% | 8.4% | ||
| Q2 24 | 30.3% | 5.3% | ||
| Q1 24 | 27.9% | -0.4% |
| Q4 25 | 13.3% | 2.3% | ||
| Q3 25 | 9.0% | 0.9% | ||
| Q2 25 | 17.8% | 5.2% | ||
| Q1 25 | 14.8% | 0.4% | ||
| Q4 24 | 20.4% | 4.1% | ||
| Q3 24 | 21.1% | 5.7% | ||
| Q2 24 | 20.8% | 3.4% | ||
| Q1 24 | 25.1% | -0.6% |
| Q4 25 | $0.51 | $0.14 | ||
| Q3 25 | $0.37 | $0.05 | ||
| Q2 25 | $0.64 | $0.32 | ||
| Q1 25 | $0.51 | $0.03 | ||
| Q4 24 | $0.74 | $0.24 | ||
| Q3 24 | $0.78 | $0.39 | ||
| Q2 24 | $0.73 | $0.21 | ||
| Q1 24 | $0.81 | $-0.03 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $282.8M | $10.3M |
| 総負債低いほど良い | $608.7M | — |
| 株主資本純資産 | $788.8M | $300.1M |
| 総資産 | $1.6B | $419.3M |
| 負債/資本比率低いほどレバレッジが低い | 0.77× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $282.8M | $10.3M | ||
| Q3 25 | $276.2M | $45.2M | ||
| Q2 25 | $231.8M | $48.9M | ||
| Q1 25 | $236.9M | $40.3M | ||
| Q4 24 | $221.6M | $40.9M | ||
| Q3 24 | $250.5M | $14.8M | ||
| Q2 24 | $217.8M | $8.7M | ||
| Q1 24 | $289.6M | $11.1M |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | $0 | ||
| Q3 24 | $596.4M | $0 | ||
| Q2 24 | $586.9M | $0 | ||
| Q1 24 | $594.0M | $0 |
| Q4 25 | $788.8M | $300.1M | ||
| Q3 25 | $776.7M | $270.0M | ||
| Q2 25 | $757.5M | $276.9M | ||
| Q1 25 | $751.3M | $272.6M | ||
| Q4 24 | $732.3M | $273.8M | ||
| Q3 24 | $727.7M | $267.6M | ||
| Q2 24 | $713.3M | $260.5M | ||
| Q1 24 | $672.4M | $261.7M |
| Q4 25 | $1.6B | $419.3M | ||
| Q3 25 | $1.7B | $372.8M | ||
| Q2 25 | $1.6B | $381.7M | ||
| Q1 25 | $1.6B | $376.5M | ||
| Q4 24 | $1.6B | $381.6M | ||
| Q3 24 | $1.5B | $373.9M | ||
| Q2 24 | $1.5B | $359.6M | ||
| Q1 24 | $1.6B | $355.5M |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | 0.00× | ||
| Q3 24 | 0.82× | 0.00× | ||
| Q2 24 | 0.82× | 0.00× | ||
| Q1 24 | 0.88× | 0.00× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $32.9M | $24.1M |
| フリーキャッシュフロー営業CF - 設備投資 | $24.6M | $17.1M |
| FCFマージンFCF / 売上 | 13.4% | 12.0% |
| 設備投資強度設備投資 / 売上 | 4.5% | 4.9% |
| キャッシュ転換率営業CF / 純利益 | 1.35× | 7.53× |
| 直近12ヶ月FCF直近4四半期 | $121.2M | $42.9M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $32.9M | $24.1M | ||
| Q3 25 | $52.6M | $13.6M | ||
| Q2 25 | $35.6M | $20.7M | ||
| Q1 25 | $35.1M | $10.6M | ||
| Q4 24 | $29.0M | $32.7M | ||
| Q3 24 | $60.0M | $17.7M | ||
| Q2 24 | $69.1M | $22.1M | ||
| Q1 24 | $55.3M | $12.0M |
| Q4 25 | $24.6M | $17.1M | ||
| Q3 25 | $47.2M | $8.0M | ||
| Q2 25 | $25.0M | $14.4M | ||
| Q1 25 | $24.4M | $3.4M | ||
| Q4 24 | $16.6M | $27.3M | ||
| Q3 24 | $46.2M | $10.8M | ||
| Q2 24 | $63.1M | $6.8M | ||
| Q1 24 | $46.5M | $5.5M |
| Q4 25 | 13.4% | 12.0% | ||
| Q3 25 | 24.6% | 6.2% | ||
| Q2 25 | 14.3% | 10.2% | ||
| Q1 25 | 14.3% | 2.5% | ||
| Q4 24 | 8.9% | 19.1% | ||
| Q3 24 | 24.1% | 7.1% | ||
| Q2 24 | 34.6% | 4.9% | ||
| Q1 24 | 27.1% | 4.0% |
| Q4 25 | 4.5% | 4.9% | ||
| Q3 25 | 2.8% | 4.3% | ||
| Q2 25 | 6.1% | 4.5% | ||
| Q1 25 | 6.3% | 5.3% | ||
| Q4 24 | 6.7% | 3.8% | ||
| Q3 24 | 7.2% | 4.5% | ||
| Q2 24 | 3.3% | 11.1% | ||
| Q1 24 | 5.1% | 4.7% |
| Q4 25 | 1.35× | 7.53× | ||
| Q3 25 | 3.03× | 11.33× | ||
| Q2 25 | 1.15× | 2.84× | ||
| Q1 25 | 1.39× | 17.67× | ||
| Q4 24 | 0.76× | 5.64× | ||
| Q3 24 | 1.48× | 2.03× | ||
| Q2 24 | 1.82× | 4.70× | ||
| Q1 24 | 1.28× | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
RNGR
| High Specification Rigs | $92.3M | 65% |
| Processing Solutions And Ancillary Services | $37.5M | 26% |
| Wireline Services | $12.4M | 9% |
